Showing results (51-60 of 432) with videos related to
Sort By:
Pageof 44
Journal of Kidney Cancer and VHL|April 30, 2026
When Effective Therapies Collide: Aorto-Esophageal Fistula After Thoracic Radiotherapy and Anti-VEGF TKI in a Long-Survivor with mRCCSimone Rota, Valentina Guadalupi, Camilla Damonte, et al.Expert Review of Anticancer Therapy|October 4, 2012
Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinomaGiuseppe Procopio, Roberto Sabbatini, Camillo Porta, et al.Expert Review of Anticancer Therapy|November 28, 2012
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-scienceCamillo Porta, Roberto Sabbatini, Giuseppe Procopio, et al.Expert Review of Anticancer Therapy|November 6, 2003
Update on the treatment of neuroendocrine tumorsEmilio Bajetta, Giuseppe Procopio, Leonardo Ferrari, et al.Tumori|February 18, 2015
Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinomaRoberto Iacovelli, Elena Verzoni, Paolo Grassi, et al.Journal of Kidney Cancer and VHL|April 17, 2024
Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer: A Case ReportSara Demurtas, Mara Frascaroli, Federico Sottotetti, et al.Frontiers in Oncology|May 20, 2020
Coronavirus: Older Persons With Cancer in Italy in the COVID-19 PandemicLucia Fratino, Giuseppe Procopio, Massimo Di Maio, et al.Journal of Bone Oncology|December 22, 2021
Bone metastases from urothelial carcinoma. The dark side of the moonMarco Stellato, Daniele Santini, Maria Concetta Cursano, et al.Drug Design, Development and Therapy|July 28, 2016
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyPaolo Grassi, Elena Verzoni, Raffaele Ratta, et al.Therapeutic Advances in Urology|April 2, 2015
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenibPaolo Grassi, Elena Verzoni, Luca Porcu, et al.Pageof 44